The subsidiary of Baiyang Pharmaceutical (301015.SZ) has signed a promotion agreement for rituximab injection with Roche Pharmaceuticals.

Baiyang Pharmaceutical (301015.SZ) announced that its wholly-owned subsidiary Peking Baiyang Zhihhe Medical Achievement Transformation Service Co., Ltd...

Zhitong FinanceFeb 13 17:05

Baiyang Pharmaceutical (301015): Multiple products showing gradual growth with deep empowerment across all channels.

The initial coverage of Baiyang Pharmaceutical has been given a "Buy" rating, with a Target Price of 31.36 yuan. Brand Operation (CSO) is the core Business of Baiyang Pharmaceutical. Unlike other competitors, the company's CSO Business deeply empowers brands and has a high added value.

HTSCJan 24 00:00

Baiyang Pharmaceutical (301015.SZ): The company has not developed any Business related to organ chips.

Gelonghui, January 13th丨Baiyang Pharmaceutical (301015.SZ) stated on the investor interaction platform that the company has not engaged in any organ chip-related Business.

Gelonghui FinanceJan 13 14:15

Baiyang Pharmaceutical (301015.SZ): Related debts passively constitute financial support after selling the equity of the controlling subsidiary.

On December 27, Gelonghui reported that Baiyang Medicine (301015.SZ) announced that its holding subsidiary, Peking Baiyang Guosheng Medical Instruments Co., Ltd. (referred to as "Baiyang Guosheng"), has sold its 57% stake in Qingdao Baiyang Shenghui Medical Devices Co., Ltd. (referred to as "Baiyang Shenghui") as of December 2024. After this transaction is completed, Baiyang Guosheng will no longer hold shares in Baiyang Shenghui, and Baiyang Shenghui will no longer be included in the company's consolidated financial statements. As of the share transfer settlement date, the company and its subsidiary Baiyang Guosheng, along with Peking Baiyang Zhihuo Medical Results Transformation Service Co., Ltd. (hereinafter referred to as "Baiyang Zhihuo"), are for the.

Gelonghui FinanceDec 27, 2024 18:14

Baiyang Pharmaceutical (301015.SZ): Appointed Li Zhen as the company's Deputy General Manager, Chief Financial Officer, and Secretary of the Board of Directors.

On December 23, Gelonghui reported that Baiyang Pharmaceutical (301015.SZ) announced that, after review by the company's Board of Directors' nomination committee, the Board of Directors agreed to appoint Mr. Li Zhen as the company's Vice General Manager, Chief Financial Officer, and Secretary of the Board of Directors, with the term starting from the date of approval in the twenty-eighth meeting of the third Board of Directors until the expiration date of the third Board of Directors' term.

Gelonghui FinanceDec 23, 2024 16:39

Express News | Baiyang Pharmaceutical: Chief Financial Officer Wang Guoqiang has resigned.

BreakingsDec 17, 2024 18:39